Yongkui Jing

Shenyang Pharmaceutical University

H指数:47

被引数:6,723

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimization of 4-Aniline Substituted Pyrido[3; 2-d]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity

4-氨基取代的吡啶并[3;2-d]嘧啶衍生物作为Pim/Mnk双抑制剂及其抗白血病活性的优化

Journal of Medicinal Chemistry

IF6.8

2026-03-240

PRE

Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate

通过一种新型青蒿素偶联物，借助血红素介导的NOXA/cyclin D1/Mcl-1轴克服venetoclax耐药性

Blood Advances

IF7.1

2025-08-140

OAAI

Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality

理性联合应用homoharringtonine，通过合成致死效应选择性靶向FLT3-ITD急性髓性白血病

Phytomedicine

IF8.3

2025-07-290

PRE

Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-08-091

PRE

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2024-06-010

PRE

Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Brusatol overcomes tyrosine kinase inhibitors resistance in myeloid leukemia cells by inhibiting translation of fast turnover protein cyclin D1 and Mcl-1

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Improved venetoclax therapy by a novel conjugate with artemisinin by NOXA-mediated reduction of Mcl-1 and cyclin D1 protein in myeloid leukemia cells

CANCER RESEARCH

IF16.6

2024-03-220

PRE

COOTO-Me (10e) acts as a molecular glue to target NCOR/HDAC3 degradation

CANCER RESEARCH

IF16.6

2024-03-220

PRE

DNMT1 determines the sensitivity of Class I HDAC inhibitor Psammaplin A to induce apoptosis and DNA damage in hematological malignant cells

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-01-184

PRE

Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance

DRUG RESISTANCE UPDATES

IF21.7

2023-05-017

PRE

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors

CELL DEATH DISCOVERY

IF7

2023-02-049

OAAI

Stilbenes with potent cytotoxicity from the seedcases of Paeonia suffruticosa Andrews

PHYTOCHEMISTRY

IF3.4

2023-01-012

PRE

Alkaloid Dimers Isolated from Thalictrum baicalense Have Antitumor Activities

从黄藻中分离出的生物碱二聚体具有抗肿瘤活性

CHINESE JOURNAL OF CHEMISTRY

IF5.5

2022-06-063

PRE

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

CELL DEATH & DISEASE

IF9.6

2022-04-2016

OAAI

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-09-1311

PRE

Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2021-01-0514

Pegaharmols A-B, Axially Chiral β-Carboline-quinazoline Dimers from the Roots of Peganum harmala

ORGANIC LETTERS

IF5

2020-09-1629

PREAI

A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects

18 β-甘草次酸与伏立诺他的结合物可降解HDAC3和HDAC6，并具有改善的抗肿瘤作用

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-02-0118

PREAI

Yongkui Jing

个人简介

教育背景

工作经历

荣誉奖项

研究方向